MedTrace Logo

Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma

NCT00210041 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-05-15

No results posted yet for this study

Summary

The purpose of this study is to determine whether association Gemcitabine-Cisplatin is effective in the treatment of penis epidermoid carcinoma loco-regionally advanced or metastatic.

Conditions

  • Genital Neoplasms, Male

Interventions

DRUG

Gemcitabine

Gemzar IV infusion 30 minutes Day 1/ Day 15 1250 mg/m²/j

DRUG

Cisplatin

Cisplatin 50 mg/m²/day 1 h IV infusion at Day 1 / Day 15

Sponsors & Collaborators

  • Institut Claudius Regaud

    lead OTHER

Principal Investigators

  • Christine Chevreau, Doctor · Institut Claudius Regaud

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2011-12-31
Completion
2012-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00210041 on ClinicalTrials.gov